PD-L1 and CD8 expression and association with outcomes in patients with BRAF V600E/K-mutant metastatic melanoma who received dabrafenib + trametinib in the randomized phase 3 COMBI-v study

Home / Abstract / PD-L1 and CD8 expression and association with outcomes in patients with BRAF V600E/K-mutant metastatic melanoma who received dabrafenib + trametinib in the randomized phase 3 COMBI-v study